Key result
Two-lead CRT-DX shows similar major event rates compared to conventional three-lead systems.
Why the study?
CRT-D carries risks of infection and lead functionality loss related to intravascular hardware, prompting evaluation of the safety and efficacy of a two-lead DX-based CRT system versus a conventional three-lead system.
Does a two-lead DX-based CRT system provide equivalent clinical outcomes compared to a conventional three-lead CRT-D system in patients meeting CRT indications without sick sinus syndrome?
Cohort (n=210)
No
Does a two-lead DX-based CRT system provide equivalent clinical outcomes compared to a conventional three-lead CRT-D system in patients meeting CRT indications without sick sinus syndrome?
A two-lead DX-based CRT system offers a safe and effective alternative to conventional three-lead CRT-D, providing equivalent clinical benefits with reduced intravascular hardware in patients without an indication for atrial pacing.
Answers are grounded in this paper and cite their sources.
May support two-lead DX CRT to reduce hardware in eligible patients; leaves open randomized confirmation of equivalence.
Background/Objectives: Cardiac resynchronization therapy with defibrillator (CRT-D) is a well-established therapy for patients with heart failure (HF) and intraventricular conduction delays, but a non-negligible risk of infection and of lead functionality loss overtime is related to intravascular hardware. The novel DX system enables atrial sensing through a floating dipole integrated into the ICD lead, reducing the intravascular burden. In this prospective non-randomized study, we aimed to evaluate the safety and efficacy of a two-lead DX-based CRT system compared to a conventional three-lead (3L) CRT-D system. Methods: A total of 210 patients meeting CRT indications and no signs of sick sinus syndrome (SSS) (baseline HR ≥ 45 bpm, or at least 85 bpm at 6 min walking test) were enrolled. Patients were assigned to either the CRT-DX or conventional 3L CRT-D group. The primary endpoint was a composite clinical response, defined as the freedom from cardiovascular death, HF hospitalization, or new-onset atrial fibrillation (AF). Results: After a mean follow-up of 46.5 ± 1.9 months, both groups had comparable clinical and instrumental outcomes. CRT-DX patients exhibited higher atrial sensing amplitudes and no significant differences in loss of lead function. Conclusions: In conclusion, the CRT-DX system provides equivalent clinical and echocardiographic benefits compared to conventional CRT-D in patients without an indication for atrial pacing. This supports the use of the DX system as a safe and effective alternative in the majority of CRT recipients.
No takes yet. Share an insight, caveat, or question.
A 2025 study conducted a cohort in Heart failure with indication for cardiac resynchronization therapy (n=210). Two-lead DX-based CRT system vs. Conventional three-lead CRT-D system was evaluated on Composite of cardiovascular death, heart failure hospitalization, or new-onset atrial fibrillation (HR 0.76, 95% CI 0.47-1.20, p=0.23). The two-lead DX-based CRT system resulted in a similar rate of the composite clinical endpoint of cardiovascular death, heart failure hospitalization, or new-onset atrial fibrillation compared to a conventional three-lead system.
Synapse has enriched 10 related papers. Consider them for comparative context: